Licensing
Enkam Pharmaceuticals, a privately held Danish company specialising in cancer and central nervous system disorders, has signed a licensing and development agreement with Stemcell Technologies Inc, a Canadian company that specialises in cell culture media, cell separation products and reagents for life science research.
Enkam’s Protein Mimetic Technology Platform will be used for the rapid creation of active peptides that are able to mimic specific functions of larger proteins, which Stemcell will commercialise. Financial terms were not disclosed.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
